Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 11 | ||||||||||
answering dept short name | Defence | ||||||||||
answering dept sort name | Defence | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Malaria: Drugs | ||||||||||
house id | 2 | ||||||||||
identifier | HL16837 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General’s 2016–17 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member printed |
|
||||||||||
title | House of Lords Tabled Parliamentary Question 2017/19 HL16837 | ||||||||||
type |
|
||||||||||
uin | HL16837 | ||||||||||
version | 3 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25277 | ||||||||||
tabling member |
|